What are you
looking for?

Back to overview
Ad hoc announcement pursuant to Art. 53 Listing Rules
Media Release Apr 02, 2024

Changes in Siegfried’s Management Team

Wolfgang Wienand is stepping down as Chief Executive Officer of Siegfried and will join Lonza in summer 2024. The Board of Directors of Siegfried has appointed CFO Reto Suter as CEO ad interim. He will assume this additional responsibility as of May 1st, 2024. The search for the new Siegfried CEO has been initiated. 

Wolfgang Wienand joined the Siegfried Group in August 2010 as Chief Scientific Officer and member of the Executive Committee. In December 2011, he took over the position of Chief Strategy Officer and was appointed CEO in January 2019. 

Andreas Casutt, Chairman of the Board of Directors: “Wolfgang Wienand has made significant contributions to the continued success of our company over the past fourteen years. Together with his team, he has consistently positioned Siegfried strategically and operationally as a reliable, innovative partner of the global pharmaceutical industry. We deeply thank him for his major contributions to Siegfried’s great development!” 

Reto Suter joined Siegfried in 2017 as Chief Financial Officer. Prior to that, he held various management positions in the industrial and financial sectors. He studied economics at the University of Zurich and the University of Washington in Seattle and holds a Doctorate in Banking and Finance. 

Andreas Casutt: “Our Board of Directors is convinced that Reto Suter will successfully lead Siegfried together with our Executive Committee in the coming months thanks to his broad professional experience and proven track record as CFO. We have a stable, strong team, a clear strategy and we confirm our outlook for 2024 and for the coming years.” 


About Siegfried 

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2023, the company achieved sales of CHF 1.272 billion and employed on 31.12.2023 more than 3700 people at twelve sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN). 

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.   

Cautionary Statements Regarding Forward-Looking Statements  

This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.


Let’s get in touch

Peter Stierli
Head Corporate Communications
Reto Suter
Chief Financial Officer
To top